Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Larazotide vs TB-500
An educational, source-based comparison of Larazotide and TB-500 — how each peptide works, what it's researched for, and what to know before going deeper.
An octapeptide zonulin antagonist that helps maintain intestinal tight junction integrity, reducing paracellular permeability triggered by gluten in celiac disease.
- Celiac disease (Phase 3 completed)
- Intestinal barrier function ('leaky gut' research)
- Environmental enteropathy
- • Not yet FDA-approved.
- • Investigational; physician oversight required.
Synthetic fragment of Thymosin Beta-4 studied for tissue and vascular repair.
A synthetic peptide fragment of Thymosin Beta-4 (Tβ4). Research suggests it upregulates actin, promotes cell migration, angiogenesis, and modulates inflammation — supporting repair in muscle, tendon, cardiac, and corneal tissue models.
- Muscle and tendon repair
- Cardiac tissue recovery (preclinical)
- Corneal and dermal wound healing
- Hair follicle stem cell activation
- • Not FDA-approved; banned by WADA.
- • Most evidence is preclinical.
Larazotide vs TB-500 — Key differences
- Class: Larazotide is classified as Gastrointestinal · Barrier, while TB-500 is Tissue Repair · Vascular.
- Primary research focus: Larazotide — celiac disease (phase 3 completed); TB-500 — muscle and tendon repair.
- Tag: Gut vs Recovery.